Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

InflammaTENSION

Financiado

Cerrado

A study of the roles of the immune and inflammatory systems in hypertension.

Hypertension is a common disease impacting 1 billion people worldwide, which leads to catastrophic cardiovascular complications. The cause of primary hypertension is unknown and the disease remains uncontrolled in many patients. B... ver más

30/04/2024

UEDIN

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

THE UNIVERSITY OF EDINBURGH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-04-30

ERC-2016-COG: ERC Consolidator Grant

I+D

Cerrada hace 8 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

UEDIN

165.24K€ | Lider

INDUSTRIAS MECANICAS ALCUDIA...

1.77M€ | Participante

UNIVERSITY OF GLASGOW

1.79M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ATHEROMOTO Vascular inflammation and atherosclerosis 240K€ Cerrado

MYCMACS Role of c Myc in atherosclerotic macrophages 50K€ Cerrado

SAF2016-80843-R ANALISIS DE MEDIADORES Y DIANAS TERAPEUTICAS IMPLICADAS EN E... 194K€ Cerrado

SAF2016-81063-R NUEVOS MEDIADORES DE LA INFLAMACION RELEVANTES EN LAS ALTERA... 97K€ Cerrado

ATHEROREMO European Collaborative Project on Inflamation and Vascular W... 15M€ Cerrado

PID2019-106773RB-I00 LA RESPUESTA INMUNE HUMORAL DURANTE LA ATEROSCLEROSIS 339K€ Cerrado

Duración del proyecto: 85 meses Fecha Inicio: 2017-03-28
Fecha Fin: 2024-04-30

Líder del proyecto

THE UNIVERSITY OF EDINBURGH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Hypertension is a common disease impacting 1 billion people worldwide, which leads to catastrophic cardiovascular complications. The cause of primary hypertension is unknown and the disease remains uncontrolled in many patients. By interrogating the key hypothesis that inflammatory dysregulation fundamentally controls development of hypertension and vascular remodelling, InflammaTENSION provides a new paradigm for the management of the disease, with the potential to lead to identification of novel therapeutic targets to control hypertension. InflammaTENSION will result in the discovery of novel biomarkers, capable of identifying patients who could benefit from such immune targeted therapies. Importantly, we already made the seminal observation that the immune system not only mediates target organ damage, but is essential for the development of hypertension. This finding has initiated numerous studies, that defined the roles of pro-inflammatory T cells, monocytes and anti-inflammatory T regulatory cells. However, our current knowledge remains very fragmented and so far has not been applied to human pathology. InflammaTENSION will for the first time advance the knowledge procured in rodent models into human studies. By combining clinical translational and model mechanistic studies it will identify novel inflammatory factors that can control immune mechanisms of hypertension. We will: (1) characterize the immunophenotypic signature of human hypertension; (2) define key concepts in cytokine biology of hypertension with TNF-α and IL-6 as key exemplars; (3) understand how chronic cytokines regulate the T cell dependent mechanisms of hypertension. InflammaTENSION will go beyond current state-of-the-art through comprehensive combination of immunology and cardiovascular medicine to create a new understanding of how the immune system may lead to human hypertension and will have major impact on the field, enabling translation of these exciting findings to clinical practice.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores